Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione
2. 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione Fumarate
3. 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione Fumarate (2:1)
4. 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione Hydrobromide
5. 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione Hydrochloride
6. 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione Monofumarate
7. 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione Monohydrobromide
8. Rs 86
9. Rs-86
10. Spiro-(n'-methylpiperidyl-4')-n-ethylsuccinimide Fumarate
1. 5asv6m91qu
2. 7524-74-5
3. 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione Hydrobromide
4. 2,8-diazaspiro(4.5)decane-1,3-dione, 2-ethyl-8-methyl-, Hydrobromide (1:1)
5. 19105-63-6
6. Chembl542883
7. Unii-5asv6m91qu
8. 2-ethyl-8-methyl-2,8-diazaspiro[4,5]decane-1,3-dione Hydrobromide
9. 2,8-diazaspiro(4,5)decane-1,3-dione, 2-ethyl-8-methyl-, Hydrobromide
10. Dtxsid00940710
11. Q27261758
12. 2-ethyl-8-methyl-2,8-diazaspiro[4.5]decane-1,3-dione--hydrogen Bromide (1/1)
Molecular Weight | 291.18 g/mol |
---|---|
Molecular Formula | C11H19BrN2O2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 1 |
Exact Mass | 290.06299 g/mol |
Monoisotopic Mass | 290.06299 g/mol |
Topological Polar Surface Area | 40.6 Ų |
Heavy Atom Count | 16 |
Formal Charge | 0 |
Complexity | 293 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Parasympathomimetics
Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?